Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Lymphoid 2Thoracic 1Gastrointestinal 1

Conditions

Lymphoma 2Carcinoma, Renal Cell 2Neoplasms 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Interferons × Clear all
NCT00001379 2025-06-19

Treatment and Natural History Study of Lymphomatoid Granulomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
94 enrolled 20 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT00577993 2020-11-16

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

M.D. Anderson Cancer Center

Phase 3 Completed
210 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT01658813 2018-03-21

5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer

Western Regional Medical Center

Phase 2 Completed
18 enrolled 2 charts
GastrointestinalGenitourinaryThoracic

Gastrointestinal Cancer Metastatic

NCT00678288 2014-12-11

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Bayer

Phase 2 Terminated
16 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00117637 2014-10-31

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Bayer

Phase 2 Completed
189 enrolled 44 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡